Busulfanum
Sickle Cell-Hemoglobin C Disease Syndrome
Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Tami D. John
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00578344CT.gov Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell-Hemoglobin C Disease Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Busulfanum (this asset) | Tami D. John | P2 | CCC · 53 |
| Hydroxyurea | Nova Laboratories Limited | P2 | BB |
| mp4co | Sangart | P2 | B |
| Tacrolimus | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Prednisone | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| Fludarabine | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Magnesium Pidolate | St. Jude Children's Research Hospital | P2 | CCC |
| Recombinant-Methionyl Human Stem Cell Factor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P1 | CC |
| Tovinontrine | Cardurion Pharmaceuticals, Inc. | P1 | CC |
+6 more in the Sickle Cell-Hemoglobin C Disease Syndrome cohort
Other indications for Busulfanum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Graft Versus Host Disease | — | P4 | BBB · 74 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Busulfanum in Sickle Cell-Hemoglobin C Disease Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/busulfanum-sickle-cell-hemoglobin-c-disease-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →